Chinese Journal of Clinical Hepatology最新文献

筛选
英文 中文
IDDF2021-ABS-0156 Sarcopenia associated with non-alcohol fatty liver disease (NAFLD) and fibrosis among adults in the United States: national health and nutrition examination survey (NHANES 2017–2018) 美国成年人中与非酒精性脂肪性肝病(NAFLD)和纤维化相关的肌肉减少症:国家健康和营养检查调查(NHANES 2017-2018)
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.97
Siyu Dai, Wen-juan Guo, Dingbo Shu, F. Chen
{"title":"IDDF2021-ABS-0156 Sarcopenia associated with non-alcohol fatty liver disease (NAFLD) and fibrosis among adults in the United States: national health and nutrition examination survey (NHANES 2017–2018)","authors":"Siyu Dai, Wen-juan Guo, Dingbo Shu, F. Chen","doi":"10.1136/gutjnl-2021-iddf.97","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.97","url":null,"abstract":"Mean values of Se intake and serum Se, tHg and MeHg were calculated; univariate and multi-variate linear regressions were conducted between CAP and Se intake, serum Se, tHg and MeHg, respectively with covariates of gender, age, ethnicity, tobacco smoke, BMI, educational level and average household income. Results Mean±SD for Se intake was 101.9±70.8 mcg, serum Se 2.4±0.33 nmol/L, serum tHg 5.6±11.4 nmol/L, serum MeHg 4.6±9.8 nmol/L, Se:tHg molar ratio of 1.1±0.8, Se: MeHg molar ratio of 1.5±1.0. The mean CAP was 257±66.2 dB/m. Univariate linear regression showed a positive association between CAP and Se intake (r=0.037, p<0.01), serum Se (r= 19.7, p<0.001), Se:MeHg molar ratio (r=-4.9, p<0.001), Se:tHg molar ratio (r= -2.8, p<0.001), respectively. After adjustment, associations between CAP and serum MeHg (r= 0.14, p<0.05), serum Se (r=13.8, p<0.001) remained statistically significant, but the associations with the molar ratios no longer existed. Conclusions Our results suggested that Se was associated with a decreased risk of NAFLD, whereas tHg and MeHg do not necessarily increase the disease risk. The molar ratios may present as early biomarkers for the prediction of NAFLD risk.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87763669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2 病毒性抑制的慢性乙型肝炎(CHB)肝功能损害患者从富马酸替诺福韦二氧丙酯(TDF)和/或其他口服抗病毒药物(OAVS)切换到替诺福韦alafenamide (TAF):来自2期的最终2年疗效和安全性结果
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.81
Y. Lim, Chun‐Yen Lin, J. Heo, H. Bae, W. Chuang, T. Tsang, C. Fournier, A. Hui, H. Trinh, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, J. Flaherty, V. Suri, A. Gaggar, Dianna M Brainard, S. Ryder, H. Janssen
{"title":"IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2","authors":"Y. Lim, Chun‐Yen Lin, J. Heo, H. Bae, W. Chuang, T. Tsang, C. Fournier, A. Hui, H. Trinh, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, J. Flaherty, V. Suri, A. Gaggar, Dianna M Brainard, S. Ryder, H. Janssen","doi":"10.1136/gutjnl-2021-iddf.81","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.81","url":null,"abstract":"(HBV DNA <LLOQ x 6 months, <20 IU/mL at screening) with moderate or severe RI or with ESRD on HD at screening while receiving TDF and/or other OAVs for 48 weeks were enrolled and switched to TAF for 96 weeks. Safety assessments including adverse events (AEs), changes in bone BMD and renal (eGFRCG, serum phosphorus serum creatinine except in ESRD patients) parameters, viral suppression, serological and biochemical responses were serially assessed. Results Of 93 patients (mod-severe RI 78; ESRD on HD 15), most (74%) were male and Asian (77%), 51% 65 y, 83% HBeAg-negative, 34% cirrhosis, and median ALT 17 U/L. Up to 24% had osteoporosis at hip and/or spine, with most having comorbidities. Twelve (13%; 11 mod-severe RI and 1 ESRD) patients discontinued the study early (5-withdrew consent, 3-deaths [none treatment-related], 2-AE, 2investigator decision). Viral suppression (HBV DNA<20IU/ mL) was maintained in all patients remaining on treatment (i.e. missing equals excluded); a high proportion had target not detected. Overall, TAF was well tolerated with no Grade 3 ,4 or serious AEs related to study treatment. Relative to baseline levels, switching to TAF resulted in small median% increases in hip/spine BMD in those with moderate to severe RI, and small median decreases in ESRD patients. 2 patients with mod-severe RI had a bone fracture (ankle, rib). Median eGFRCG increased while urinary markers of proximal tubular function progressively decreased in mod-severe RI patients. Conclusions Renally-impaired CHB patients, including ESRD patients on HD, who were switched to TAF from TDF and/or other OAVs maintained high rates of viral suppression, and bone and renal parameters remained stable or slightly improved after 2 years of treatment.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90877222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0159 The effect of curcumin supplement among overweight/obese non-alcoholic fatty liver disease (NAFLD) patients 姜黄素补充剂对超重/肥胖非酒精性脂肪性肝病(NAFLD)患者的影响
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.98
Eduward Thendiono
{"title":"IDDF2021-ABS-0159 The effect of curcumin supplement among overweight/obese non-alcoholic fatty liver disease (NAFLD) patients","authors":"Eduward Thendiono","doi":"10.1136/gutjnl-2021-iddf.98","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.98","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82246883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0010 A meta-analysis and meta-regression between liver resection and liver transplant within milian criteria 肝切除和肝移植之间的meta分析和meta回归符合milian标准
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.62
C. Ng, J. H. Koh, Y. Ong, W. Lim, Darren Jun Hao Tan, M. Muthiah, N. Syn, Brian Goh, Dan-chi Huang
{"title":"IDDF2021-ABS-0010 A meta-analysis and meta-regression between liver resection and liver transplant within milian criteria","authors":"C. Ng, J. H. Koh, Y. Ong, W. Lim, Darren Jun Hao Tan, M. Muthiah, N. Syn, Brian Goh, Dan-chi Huang","doi":"10.1136/gutjnl-2021-iddf.62","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.62","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83530539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0019 An epidemiological meta-analysis on the worldwide prevalence, resistance and outcomes of spontaneous bacterial peritonitis in cirrhosis 肝硬化自发性细菌性腹膜炎的全球患病率、耐药性和结局的流行病学荟萃分析
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.64
C. Ng, Phoebe Wen Lin Tay, J. Xiao, Darren Jun Hao Tan, Yan Nerng Lye, W. Lim, Vanessa Xin Yi Teo, Ryan Rui Yang Heng, Marcus Wei Xuan Yeow, Lionel Hon Wai Lum, Eunice Xiang Xuan Tan, G. S. Kew, G. Lee, M. Muthiah
{"title":"IDDF2021-ABS-0019 An epidemiological meta-analysis on the worldwide prevalence, resistance and outcomes of spontaneous bacterial peritonitis in cirrhosis","authors":"C. Ng, Phoebe Wen Lin Tay, J. Xiao, Darren Jun Hao Tan, Yan Nerng Lye, W. Lim, Vanessa Xin Yi Teo, Ryan Rui Yang Heng, Marcus Wei Xuan Yeow, Lionel Hon Wai Lum, Eunice Xiang Xuan Tan, G. S. Kew, G. Lee, M. Muthiah","doi":"10.1136/gutjnl-2021-iddf.64","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.64","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87157004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0084 Tuberculosis as a common cause of post-liver transplant ascites 结核病是肝移植后腹水的常见原因
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.84
T. Sowmya
{"title":"IDDF2021-ABS-0084 Tuberculosis as a common cause of post-liver transplant ascites","authors":"T. Sowmya","doi":"10.1136/gutjnl-2021-iddf.84","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.84","url":null,"abstract":"Background To assess the quality of life (QoL) of patients with hepatocellular carcinoma (HCC) by the European Organi-zation for the Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ- C30). Methods A prospective study was conducted from August 2020 to August 2021. We evaluated the QoL of 30 patients diagnosed of HCC at Bach Mai and Hanoi Medical University Hospital after a month of treatment. EORTC-QLQ C30 items were converted to scores according to an available formula, the total score for each section ranged from 0 to 100. A low functional score reflected a low QoL, while a lower symptom score indicated a higher QoL. The overall EORTC score (C30 index score) would be calculated according to the available formula. The lower the C30 index score was, the better the QoL would be. and","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73377122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
IDDF2021-ABS-0070 Predictive performance of the hap score at patients with hepatocellular carcinoma following trans-arterial chemoembolisation (TACE) 肝细胞癌经动脉化疗栓塞(TACE)后hap评分的预测性能
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.77
Anh Tran Ngoc, H. Trung, Lieu Dau Quang
{"title":"IDDF2021-ABS-0070 Predictive performance of the hap score at patients with hepatocellular carcinoma following trans-arterial chemoembolisation (TACE)","authors":"Anh Tran Ngoc, H. Trung, Lieu Dau Quang","doi":"10.1136/gutjnl-2021-iddf.77","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.77","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"150 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79082647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0040 Less liver fibrosis marker increment in overweight chronic hepatitis b patients observed by age-adjusted fibrosis-4 index 年龄调整纤维化-4指数观察超重慢性乙型肝炎患者肝纤维化标志物增加较少
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.68
Tasia Liu
{"title":"IDDF2021-ABS-0040 Less liver fibrosis marker increment in overweight chronic hepatitis b patients observed by age-adjusted fibrosis-4 index","authors":"Tasia Liu","doi":"10.1136/gutjnl-2021-iddf.68","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.68","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74771880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0184 Global incidence and risk factors of pancreatic cancer among young adults: an epidemiological study 年轻人胰腺癌的全球发病率和危险因素:一项流行病学研究
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.101
Junjie Huang, Alfonse Ngai, Veeleah Lok, Xianjing Liu, Lin Zhang, Jinqiu Yuan, Wanghong Xu, Zhi‐Jie Zheng, Martin C. S. Wong
{"title":"IDDF2021-ABS-0184 Global incidence and risk factors of pancreatic cancer among young adults: an epidemiological study","authors":"Junjie Huang, Alfonse Ngai, Veeleah Lok, Xianjing Liu, Lin Zhang, Jinqiu Yuan, Wanghong Xu, Zhi‐Jie Zheng, Martin C. S. Wong","doi":"10.1136/gutjnl-2021-iddf.101","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.101","url":null,"abstract":"IDDF2021-ABS-0184 Figure 1 Global incidence of youngonset pancreatic cancer in 2020 Abstracts Gut 2021;70(Suppl 2):A1–A150 A91 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F .02 on 2 S etem er 221. D ow nladed fom Methods A cross-sectional study of all eligible LT recipients from 2008 to 2020 in a leading transplant centre in Singapore was conducted to determine the vaccine response in HBV-naïve subjects. A standardised workflow was devised to identify barriers in vaccination and response monitoring. Transplant coordinators and pharmacists assisted physicians to identify and prescribe CDC-recommended vaccinations using a template, which include Engerix 40mcg of three doses, followed by rechecking anti-HBs titre one month after. A second 3-dose Engerix regimen was given if anti-HBs remains <10 mIU/mL. Non-responder is defined as failure to achieve protective anti-HBs titre after completing two cycles. Results Of the 279 LT recipients, we excluded patients not on follow-up and patients with anti-HBc positivity. 75 patients were included. Prior to vaccination implementation, 9/75 (12%) were not checked for anti-HBs. Of the 66 checked, 40 required vaccination. 29/40 (72.5%) were started on the first cycle, and 21/40 (52.5%) completed. 11/20 (55%) patients were initiated on the second cycle. Post workflow implementation, 40 needed vaccination. 34/40 (85%) were started on the first cycle and 24/40 (60%) completed. 18/23 (78.3%) were started on a second cycle. 3/4 (75%) were non-responders (IDDF2021-ABS-0190 Figure 1). Our implementation coincided with the COVID-19 pandemic where more teleconsultation was used. COVID-19 vaccination was also prioritised over HBV vaccination. We postulate that these results would be further improved once physical consultations resumed. Conclusions The development of a standardised workflow can lead to improvement in anti-HBs testing and compliance to vaccination post-LT. These findings may be useful for other patients who are on long-term immunosuppression. Continual efforts from the multidisciplinary team are required to ensure the sustainability of effect. IDDF2021-ABS-0203 A SCREENING MODEL FOR OBSTRUCTIVE SLEEP APNEA ON THE BASIS OF FATTY LIVER DISEASE-RELATED PARAMETERS Yang-Bor Lu*, Yu-Chieh Weng, Yung-Ning Huang, Hsiung-Ying Huang, PeiTing Cheng, Hui-Shan Hsieh, Ming-Shao Tsai. Department of Digestive Disease, Xiamen Chang Gung Hospital, Xiamen, China; Hepatobiliary and Pancreatic Unit, Xiamen Chang Gung Hospital, Xiamen, China; Department of Pulmonary and Critical Care Medicine, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Formosa Biomedical Technology Corp., Taipei, Taiwan; Department of Otolaryngology-Head and Neck Surgery, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Department of Otolaryngology-Head and Neck Surgery, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyua","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84852702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0102 Retrospective analysis of characteristics, indications and outcomes of ercp in a tertiary referral center of Saudi Arabia 沙特阿拉伯某三级转诊中心ercp的特点、适应证和转归回顾性分析
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.90
Laeeque Ahmed, Ahmed Basalim, N. Alwagdani, Bsaim Altirkistani, Ziyad M. Albassam, Mohammed A Almatrafi, Faisal S Alrubaei, Adnan Alzanbagi
{"title":"IDDF2021-ABS-0102 Retrospective analysis of characteristics, indications and outcomes of ercp in a tertiary referral center of Saudi Arabia","authors":"Laeeque Ahmed, Ahmed Basalim, N. Alwagdani, Bsaim Altirkistani, Ziyad M. Albassam, Mohammed A Almatrafi, Faisal S Alrubaei, Adnan Alzanbagi","doi":"10.1136/gutjnl-2021-iddf.90","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.90","url":null,"abstract":"IDDF2021-ABS-0116 Figure 2 Abstract IDDF2021-ABS-0116 Figure 3 AbstractsIDDF2021-ABS-0116 Figure 3 Abstracts Gut 2021;70(Suppl 2):A1–A150 A85 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 92 on 2 S etem er 221. D ow nladed fom 32 studies described tumors with a specified primary, with gastric cancer being the most common. (IDDF2021-ABS-0116 Figure 1) Pooled data showed that the 3and 5-year OS were 45% (95% CI 0.40-0.50) and 35% (95% CI 0.31-0.19), (IDDF2021-ABS-0116 Figure 2, IDDF2021-ABS-0116 Figure 3) respectively, whereas the 3and 5-year DFS were 33% (95% CI 0.29-20.37) and 27% (95% CI 0.23-0.32), respectively (IDDF2021-ABS-0116 Figure 4, IDDF2021-ABS-0116 Figure 5). The postoperative morbidity rate was 24% (95% CI 0.20-0.29), whereas the 30-day mortality was 2% (95% CI 0.01-0.03). Gastric cancer with liver metastasis had 3-year and 5-year OS of 39% (95% CI 0.32-0.46) and 25% (95% CI 0.20-0.31). Conclusions Hepatectomy for NCNNLM may achieve favourable survival outcomes, with low surgical morbidities and mortalities in selected patients. IDDF2021-ABS-0118 FACTORS ASSOCIATED WITH THE PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DETECTED IN JAPANESE ADULTS UNDERGOING HEALTH","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"66 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91511588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信